Literature DB >> 12900216

Getting muscles moving again after botulinum toxin: novel therapeutic challenges.

Patrick G Foran1, Bazbek Davletov, Frederic A Meunier.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12900216     DOI： 10.1016/s1471-4914(03)00113-8

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


× No keyword cloud information.
  20 in total

1.  Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting.

Authors:  Mengfei Ho; Li-Hsin Chang; Melissa Pires-Alves; Baskaran Thyagarajan; Jordan E Bloom; Zhengrong Gu; Karla K Aberle; Sasha A Teymorian; Yuka Bannai; Steven C Johnson; Joseph J McArdle; Brenda A Wilson
Journal:  Protein Eng Des Sel       Date:  2010-11-04       Impact factor: 1.650

2.  Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism.

Authors:  Callista B Harper; Sally Martin; Tam H Nguyen; Shari J Daniels; Nickolas A Lavidis; Michel R Popoff; Gordana Hadzic; Anna Mariana; Ngoc Chau; Adam McCluskey; Phillip J Robinson; Frederic A Meunier
Journal:  J Biol Chem       Date:  2011-08-05       Impact factor: 5.157

3.  A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.

Authors:  Igor Opsenica; James C Burnett; Rick Gussio; Dejan Opsenica; Nina Todorović; Charlotte A Lanteri; Richard J Sciotti; Montip Gettayacamin; Nicoletta Basilico; Donatella Taramelli; Jonathan E Nuss; Laura Wanner; Rekha G Panchal; Bogdan A Solaja; Sina Bavari
Journal:  J Med Chem       Date:  2011-01-25       Impact factor: 7.446

Review 4.  Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.

Authors:  Brenda A Wilson; Mengfei Ho
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

5.  Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?

Authors:  Brian E Lacy; Kirsten Weiser; Abigail Kennedy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-04

6.  Pharmacophore Refinement Guides the Rational Design of Nanomolar-Range Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease.

Authors:  Jonathan E Nuss; Yuxiang Dong; Laura M Wanner; Gordon Ruthel; Peter Wipf; Rick Gussio; Jonathan L Vennerstrom; Sina Bavari; James C Burnett
Journal:  ACS Med Chem Lett       Date:  2010-10-14       Impact factor: 4.345

7.  Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: extending towards the β-exosite.

Authors:  Garry R Smith; Dejan Caglič; Petr Capek; Yan Zhang; Sujata Godbole; Allen B Reitz; Tobin J Dickerson
Journal:  Bioorg Med Chem Lett       Date:  2012-04-11       Impact factor: 2.823

8.  The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease.

Authors:  Igor Opsenica; Vuk Filipovic; Jon E Nuss; Laura M Gomba; Dejan Opsenica; James C Burnett; Rick Gussio; Bogdan A Solaja; Sina Bavari
Journal:  Eur J Med Chem       Date:  2012-03-30       Impact factor: 6.514

9.  Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A.

Authors:  Mengfei Ho; Cheong-Hian Goh; Michael C Brothers; Shihua Wang; Ryan L Young; Yuxiang Ou; Juliana Nga-Man Lui; Marinos Kalafatis; Xiuwan Lan; Abigail E Wolf; Chad M Rienstra; Brenda A Wilson
Journal:  Protein Sci       Date:  2012-03       Impact factor: 6.725

Review 10.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.